Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Broad and deep portfolio of highly differentiated product candidates aligned with needs of patients and doctorsRobust pipeline includes 4 development programs addressing 7 dermatological diseases,...
-
Phase 3 trials’ topline data anticipated in the first quarter of 2021 and potential New Drug Application (NDA) submission anticipated by the end of 2021Roflumilast cream potential “Best in Class”...
-
WESTLAKE VILLAGE, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments...
-
Once-daily roflumilast cream demonstrated favorable safety and tolerability over 52 to 64 weeks of treatmentAt 52 to 64 weeks of treatment, over one-third of subjects demonstrated IGA Success and 45%...
-
Roflumilast foam demonstrated statistically significant improvement on the trial’s primary and multiple secondary endpointsOnce-daily roflumilast foam demonstrated a favorable safety and tolerability...
-
WESTLAKE VILLAGE, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments...
-
Pivotal Phase 3 data in plaque psoriasis anticipated in first quarter of 2021Pivotal Phase 3 trials in atopic dermatitis anticipated to begin in late 2020 or early 2021Recent positive Phase 2 data in...
-
WESTLAKE VILLAGE, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a medical dermatology company developing innovative treatments for patients with...
-
In Phase 2b study of patients with plaque psoriasis, roflumilast cream demonstrated rapid and clinically significant reduction in the severity and burden of itch and itch-related sleep loss as well as...
-
Data highlight potential of roflumilast cream as a “Best in Class” topical PDE4 inhibitor for the treatment of atopic dermatitis and plaque psoriasisTwo oral presentations and one poster at the...